Navigation Links
Successful Islet Cell Transplant in Mice With Type 1 Diabetes

Researchers have determined a way to pre-screen cancer patients to see if they are suitable candidates for proteasome inhibitors, a promising class of anti-cancer drugs// . They propose to test for p53, a well-known tumor-suppressor protein that is broken down by cellular machinery called proteasomes.

In cancer patients whose tumors do not produce p53, proteasome inhibitors might be ineffective. This patient group could be spared unnecessary treatment with possible harmful side effects. On the other hand, proteasome inhibitors are highly effective against lymphomas that do have the ability to produce p53.

“Proteasomes resemble paper shredders – they break down proteins such as p53 into smaller pieces,” says senior author Andrei Thomas-Tikhonenko, PhD, Associate Professor of Pathology. “A proteosome inhibitor effectively jams the shredder so that p53 is not immediately broken down.”

In this study, the research team used a mutant strain of mice in which p53 activity can be switched on and off. “In principle, tumors in these mice could be obliterated by turning p53 back on,” says Thomas-Tikhonenko. “The problem was that a protein called MDM2 sent p53 into the teeth of the proteasome shredder.” The proteasome inhibitor bortezomib (Velcade?) causes this jamming process and restores p53 function. However, if p53 was inactivated in the mice, bortezomib treatment failed to kill tumors. Similar effects were seen with cell lines derived from human Burkitt’s lymphomas. When implanted into mice, these lymphoma cells were highly sensitive to the proteasome inhibitor, but as soon as p53 was removed, the inhibitor had no effect.

“These findings have important implications for clinical practice,” Thomas-Tikhonenko adds. “Bortezomib is approved by the Food and Drug Administration for the treatment of multiple myeloma, another cancer of lymphoid cells. Yet, only a fraction of multiple myeloma patients respond to the drug.”

The researchers speculate that responsive myelomas are the ones retaining the p53 protein, which gets stabilized during treatment and triggers self-destruction of cancerous cells. “If confirmed experimentally, our hypothesis will serve to pre-select patients with the best chances of success – those with p53 – and spare the rest – those without p53 – the severe side effects of bortezomib therapy,” explains Thomas-Tikhonenko.

There are two ways, suggest the researchers, to test for p53 production in cancer patients. First, if MDM2 is expressed at abnormally high levels, it is a good indicator that p53 is constantly being made. Second, genetic tests can also be conducted to see if the malignant cells still have the gene for p53 or if the portion of the chromosome on which p53 is found has been deleted.

Sourc-Newswise
SRM
'"/>




Related medicine news :

1. Plastic Sling Has Proved Successful In Improving Aging Of The Neck
2. Successful creation of human embryos from a single parent for the first time
3. French Doctors Successfully Separate Twins Joined At Spine
4. Alzheimer’s disease trial With EVT 101 For Successfully Complete
5. Overweight Briton Underwent Successful Surgery In India Being Denied By NHS
6. First Ever Face Transplant In China Successfully Performed
7. Third Arm Removed Successfully
8. Pancreatic Cancer Surgery Successful in 80-Year-Olds
9. Australian Surgeons Successfully Conduct Worlds First Triple Organ Transplant
10. Mental Health Providers Can Be Successfully Located With Pediatricians
11. Anti-Obesity Vaccine Successful In Rats
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... CareSet Labs today ... e-prescribing as measured in Part D Medicare data. The dataset, called PaPR (Providers ... using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data set aggregates ...
(Date:4/26/2017)... ... 2017 , ... The National Business Research Institute (NBRI) is ... Emergency Medical Technicians and welcomes this organization to the NBRI Circle of ... Ph.D. , CEO & Organizational Psychologist at NBRI. “This award is a result ...
(Date:4/26/2017)... City, NJ (PRWEB) , ... April 26, 2017 , ... ... offers an easy way to get nutrients from SUPERFOODS! , RawTrition is ... body at the cellular level because the body recognizes its raw form (unlike the ...
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... 25, 2017 , ... Splashtop Inc. , the worldwide ... new addition to the Mirroring360 product family combines device screen mirroring with screen ... enables educators, business professionals and individuals to stream or mirror app screens, music, ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
(Date:4/18/2017)... 18, 2017  Socionext Inc. and SOINN Inc. ... 2016, in which Socionext extracts and delivers biometrics ... achieved initial results in reading ultrasound images from ... SOINN. The results will be introduced at Medtec ... at booths 4505 & 4507. In ...
Breaking Medicine Technology: